Form D · Pharmaceuticals
Ethicann Pharmaceuticals Inc. / DE
Bethesda, MD · CIK 0001967784
Offering snapshot reported Mar 6, 2023 · SEC filing
- Reported sold
- Yet to sell Indefinite offering
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 6, 2023 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-474899
Convertible promissory note with a warrant
Source: Form D, filed Mar 6, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Douglas Kawahara | Director, Executive |
| Dwayne Lashyn | Director |
| Bruce Mackler | Director, Executive, Promoter |
| Neil Maruoka | Director |
| Michael Myers | Director |
| Brandon Price | Director, Executive, Promoter |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
7710 Woodmont Ave Suite 910
Bethesda, MD, 20814
Bethesda, MD, 20814